GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Cooper Companies Inc (NAS:COO) » Definitions » Return-on-Tangible-Equity

The Cooper (The Cooper) Return-on-Tangible-Equity : 15.14% (As of Jan. 2024)


View and export this data going back to 1983. Start your Free Trial

What is The Cooper Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. The Cooper's annualized net income for the quarter that ended in Jan. 2024 was $325 Mil. The Cooper's average shareholder tangible equity for the quarter that ended in Jan. 2024 was $2,145 Mil. Therefore, The Cooper's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 was 15.14%.

The historical rank and industry rank for The Cooper's Return-on-Tangible-Equity or its related term are showing as below:

COO' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.44   Med: 129.62   Max: 366.83
Current: 14.44

During the past 13 years, The Cooper's highest Return-on-Tangible-Equity was 366.83%. The lowest was 14.44%. And the median was 129.62%.

COO's Return-on-Tangible-Equity is ranked better than
77.31% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 1.97 vs COO: 14.44

The Cooper Return-on-Tangible-Equity Historical Data

The historical data trend for The Cooper's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Cooper Return-on-Tangible-Equity Chart

The Cooper Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity 184.93 16.16 15.10

The Cooper Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.45 8.60 17.16 15.76 15.14

Competitive Comparison of The Cooper's Return-on-Tangible-Equity

For the Medical Instruments & Supplies subindustry, The Cooper's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Cooper's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where The Cooper's Return-on-Tangible-Equity falls into.



The Cooper Return-on-Tangible-Equity Calculation

The Cooper's annualized Return-on-Tangible-Equity for the fiscal year that ended in Oct. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Oct. 2023 )  (A: Oct. 2022 )(A: Oct. 2023 )
=294.2/( (1679.7+2216 )/ 2 )
=294.2/1947.85
=15.10 %

The Cooper's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=324.8/( (2216+2073.8)/ 2 )
=324.8/2144.9
=15.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


The Cooper  (NAS:COO) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


The Cooper Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of The Cooper's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


The Cooper (The Cooper) Business Description

Traded in Other Exchanges
Address
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, USA, 94583
The Cooper Companies is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.
Executives
Gary S Petersmeyer director 3400 CENTRAL AVENUE, SANTA CLARA CA 95051
Robert S Weiss director, officer: EVP and CFO 6140 STANERIDGE MALL RES #590, PLEASSANTON CA 94503
Agostino Ricupati officer: Sr. VP, Finance & Tax C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Warner Gerard H Iii officer: President, CooperVision, Inc. C/O COOPER COMPANIES INC., 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583
Jody S Lindell director 2536 FILLMORE ST., SAN FRANCISCO CA 94115
Cynthia L Lucchese director 7966 N. ILLINOIS STREET, INDIANAPOLIS IN 46260
Nicholas Khadder officer: VP, General Counsel & Corp Sec 2836 JOHNSON AVENUE, ALAMEDA CA 94501
Daniel G Mcbride officer: VP and Senior Counsel 5 EL CORTE, ORINDA CA 94563
Brian G Andrews officer: Treasurer 4300A 17TH STREET, SAN FRANCISCO CA 94114
Maria Rivas director C/O MEDIDATA SOLUTIONS, INC., 350 HUDSON STREET, 9TH FLOOR, NEW YORK NY 10014
White Albert G Iii officer: VP & Treasurer 6790, SPRINGDALE COURT, VICTOR NY 14564
Teresa S Madden director 414 NICOLLET MALL, MINNEAPOLIS MN 55401
Robert D Auerbach officer: President, CSI C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Holly R Sheffield officer: EVP, CSO C/O THE COOPER COMPANIES, INC., 6140 STONERIDGE MALL ROAD, SUITE 590, PLEASANTON CA 94588
Mark J Drury officer: VP, General Counsel & Sec. C/O COOPERCOMPANIES, 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON CA 94583

The Cooper (The Cooper) Headlines